Quarterly report pursuant to Section 13 or 15(d)

Segments

v3.20.2
Segments
6 Months Ended
Jun. 30, 2020
Segment Reporting [Abstract]  
SEGMENTS SEGMENTS
We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of our clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
  For the three months ended June 30, For the six months ended June 30,
(In thousands) 2020 2019 2020 2019
Revenue from services:
Pharmaceutical $ —    $ —    $ —    $ —   
Diagnostics 250,971    178,458    421,811    357,349   
Corporate —    —    —    —   
$ 250,971    $ 178,458    $ 421,811    $ 357,349   
Revenue from products:
Pharmaceutical $ 29,356    $ 28,680    $ 60,430    $ 53,981   
Diagnostics —    —    —    —   
Corporate —    —    —    —   
$ 29,356    $ 28,680    $ 60,430    $ 53,981   
Revenue from transfer of intellectual property and other:
Pharmaceutical $ 14,686    $ 19,230    $ 24,239    $ 37,490   
Diagnostics 6,194    —    6,194    —   
Corporate —    —    —    —   
$ 20,880    $ 19,230    $ 30,433    $ 37,490   
Operating loss:
Pharmaceutical $ (5,996)   $ (8,556)   $ (20,121)   $ (38,033)  
Diagnostics 40,935    (28,013)   22,803    (61,582)  
Corporate (7,760)   (10,691)   (16,263)   (22,962)  
$ 27,179    $ (47,260)   $ (13,581)   $ (122,577)  
Depreciation and amortization:
Pharmaceutical $ 7,119    $ 7,382    $ 14,240    $ 14,908   
Diagnostics 15,147    16,260    30,019    32,530   
Corporate —    19    59    39   
$ 22,266    $ 23,661    $ 44,318    $ 47,477   
Loss from investment in investees:
Pharmaceutical $ (189)   $ (271)   $ (323)   $ (2,125)  
Diagnostics —    —    —    —   
Corporate —    —    —    —   
$ (189)   $ (271)   $ (323)   $ (2,125)  
Revenues:
United States $ 265,890    $ 184,310    $ 446,761    $ 369,203   
Ireland 16,847    22,174    28,749    42,707   
Chile 11,152    9,051    22,002    16,915   
Spain 4,136    4,876    8,292    9,294   
Israel 1,183    3,768    2,890    6,884   
Mexico 1,866    2,058    3,708    3,589   
Other 133    131    272    228   
$ 301,207    $ 226,368    $ 512,674    $ 448,820   
(In thousands) June 30,
2020
December 31,
2019
Assets:
Pharmaceutical $ 1,148,151    $ 1,174,639   
Diagnostics 1,121,202    1,035,112   
Corporate 54,381    99,521   
$ 2,323,734    $ 2,309,272   
Goodwill:
Pharmaceutical $ 236,790    $ 237,131   
Diagnostics 434,809    434,809   
Corporate —    —   
$ 671,599    $ 671,940   
No customer represented more than 10% of our total consolidated revenue during the six months ended June 30, 2020 and 2019. As of June 30, 2020 and December 31, 2019, no customer represented more than 10% of our accounts receivable balance.